Previous Article | Next Article ![]()
Infection and Immunity, January 2000, p. 227-232, Vol. 68, No. 1
Molecular Immunology Group, Institute of
Molecular Medicine, Nuffield Department of Medicine, University of
Oxford, John Radcliffe Hospital, Oxford OX3
9DU,1 and Wellcome Trust Centre for
Human Genetics, Headington, Oxford OX3 7BN,2
United Kingdom; Biomedical Parasitology, Institut Pasteur,
Paris, France3; Ifakara Centre, National
Institute of Medical Research, Kilombero,
Tanzania4; and Medical Research Council
Laboratories, Fajara, The Gambia5
Received 14 December 1998/Returned for modification 17 February
1999/Accepted 14 October 1999
The development of an effective preerythrocytic vaccine against
Plasmodium falciparum malaria is likely to require
inclusion of components from several preerythrocytic antigens. The
association of HLA-B53 with resistance to severe malaria in West Africa
provided evidence that HLA class I-restricted CD8+ T-cell
responses play a role in protective immunity in African children,
supporting data from rodent models of malaria. Previously, a single
epitope from liver-stage-specific antigen 1 (LSA-1) has been shown to
be recognized by HLA-B53-specific cytotoxic T lymphocytes (CTL), but
HLA-B53 epitopes were not found in four other antigens. In this study
we measured CTL responses to peptides from the recently sequenced
antigen liver-stage antigen 3 (LSA-3) and identified in it a new
epitope restricted by HLA-B53. Several CTL epitopes restricted by other
class I types were also identified within LSA-3 in studies in The
Gambia and Tanzania. CTL were also identified to an additional P. falciparum antigen, exported protein 1 (Exp-1), the homologue of
which is a protective antigen in a rodent model of malaria. These
findings emphasize the diversity of P. falciparum antigens
recognized by CD8+ T cells in humans and support the
inclusion of components from several antigens in new CTL-inducing
vaccines against malaria.
0019-9567/0/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Cytotoxic T-Lymphocyte Epitopes for HLA-B53 and
Other HLA Types in the Malaria Vaccine Candidate Liver-Stage
Antigen 3
*
Corresponding author. Present address: Immunogenetics
Section, Division of AIDS, STD and TB Laboratory Research, National Center for Infectious Diseases, Centers for Disease Control and Prevention, MS-A25, Atlanta, Georgia 30333. Phone: (404) 639-2150. Fax:
(404) 639-2108. E-mail: Mha3{at}cdc.gov.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»